During a recent US Senate Finance Committee meeting, senators had an opportunity to question seven pharmaceutical industry leaders about critical drug pricing questions. While the group addressed many critical issues concerning drug pricing policy, other subjects were omitted from the discussion. Pink Sheet’s editors have compiled a list of questions they would have liked to see addressed at the meeting, which was an unusual opportunity to question industry leaders en masse.  Tap into information about the meeting and these unanswered questions here.